Cargando…

Correction to: Ozanimod: A Review in Ulcerative Colitis

Detalles Bibliográficos
Autor principal:	Paik, Julia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2022
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9499879/ https://www.ncbi.nlm.nih.gov/pubmed/36050602 http://dx.doi.org/10.1007/s40265-022-01772-6

Ejemplares similares

Ozanimod: A Review in Ulcerative Colitis
por: Paik, Julia
Publicado: (2022)

Ozanimod-Associated Iatrogenic Kaposi Sarcoma in a Patient With Ulcerative Colitis
por: Sandlow, Sarah, et al.
Publicado: (2023)

Ozanimod Maintenance Therapy After Cyclosporine Induction in Acute Severe Ulcerative Colitis
por: Cohen, Nathaniel A., et al.
Publicado: (2022)

Network pharmacology and in silico pharmacokinetic prediction of Ozanimod in the management of ulcerative colitis: A computational study
por: Sivasakthi, Priya, et al.
Publicado: (2022)

Ozanimod Therapy in a Patient With Ulcerative Colitis and Multiple Sclerosis: Hitting 2 Birds With 1 Stone
por: Vuyyuru, Sudheer K., et al.
Publicado: (2023)

Su1500: COMPARATIVE EFFICACY AND SAFETY OF OZANIMOD AND USTEKINUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS
por: Dubinsky, Marla C., et al.
Publicado: (2022)

Su1480: TREATMENT-EMERGENT COVID-19 INFECTIONS IN OZANIMOD ULCERATIVE COLITIS AND MULTIPLE SCLEROSIS CLINICAL TRIALS
por: Ungaro, Ryan C., et al.
Publicado: (2022)

Ozanimod for multiple sclerosis
Publicado: (2021)

Correction to: Management of elderly ulcerative colitis in Japan
por: Higashiyama, Masaaki, et al.
Publicado: (2019)

"Hit smart and early" mit Ozanimod
por: Ottenjann, Henrike
Publicado: (2023)

Correction: Vedolizumab for Ulcerative Colitis: Treatment Outcomes from the VICTORY Consortium
por: Narula, Neeraj, et al.
Publicado: (2019)

Neuroprotection by Ozanimod Following Intracerebral Hemorrhage in Mice
por: Wang, Fei, et al.
Publicado: (2022)

Correction to: The LUCID study: living with ulcerative colitis; identifying the socioeconomic burden in Europe
por: Ruiz-Casas, Leonardo, et al.
Publicado: (2021)

Correction to: Identification and immunological characterization of cuproptosis-related molecular clusters in ulcerative colitis
por: Pu, Yunfei, et al.
Publicado: (2023)

Long-Term Efficacy and Safety of Ozanimod in Moderately to Severely Active Ulcerative Colitis: Results From the Open-Label Extension of the Randomized, Phase 2 TOUCHSTONE Study
por: Sandborn, William J, et al.
Publicado: (2021)

Correction to: Protective effect of 6-paradol in acetic acid-induced ulcerative colitis in rats
por: Rafeeq, Misbahuddin, et al.
Publicado: (2021)

Correction: The insoluble excretion of multi-matrix system mesalazine preparations in patients with ulcerative colitis
por: Ohtaki, Yuichiro, et al.
Publicado: (2023)

"Hit smart and early" - MS-Therapie mit Ozanimod
por: Ottenjann, Henrike
Publicado: (2023)

Correction: Tofacitinib for the treatment of moderately to severely active ulcerative colitis: a systematic review, network meta-analysis and economic evaluation
Publicado: (2020)

Correction to: Dapagliflozin: A Review in Type 1 Diabetes
por: Paik, Julia, et al.
Publicado: (2019)

An Overview of the Efficacy and Safety of Ozanimod for the Treatment of Relapsing Multiple Sclerosis
por: Fronza, Marzia, et al.
Publicado: (2021)

Correction to: Damoctocog Alfa Pegol: A Review in Haemophilia A
por: Paik, Julia, et al.
Publicado: (2019)

Correction to: Comparative efficacy of advanced treatments in biologic-naïve or biologic-experienced patients with ulcerative colitis: a systematic review and network meta-analysis
por: Lu, Xiaoyan, et al.
Publicado: (2023)

Correction to: Characterization of Creatine Kinase Levels in Tofacitinib‑Treated Patients with Ulcerative Colitis: Results from Clinical Trials
por: Panaccione, Remo, et al.
Publicado: (2020)

Correction: Vedolizumab in Japanese patients with ulcerative colitis: A Phase 3, randomized, double-blind, placebo-controlled study
por: Motoya, Satoshi, et al.
Publicado: (2019)

Correction to: Real-world characteristics, treatment experiences and corticosteroid utilisation of patients treated with tofacitinib for moderate to severe ulcerative colitis
por: Chiorean, Michael V., et al.
Publicado: (2022)

Correction: MicroRNAs Expression in the Ileal Pouch of Patients with Ulcerative Colitis Is Robustly Up-Regulated and Correlates with Disease Phenotypes
por: Ben-Shachar, Shay, et al.
Publicado: (2016)

Correction: The association between antigenemia, histology with immunohistochemistry, and mucosal PCR in the diagnosis of ulcerative colitis with concomitant human cytomegalovirus infection
por: Yamakawa, Tsukasa, et al.
Publicado: (2023)

Correction: Protective effect and mechanism insight of purified Antarctic krill phospholipids against mice ulcerative colitis combined with bioinformatics
por: Huang, Rong, et al.
Publicado: (2023)

Correction: Bowel frequency (night) and urgent defecation are improved by budesonide foam in patients with ulcerative colitis: a retrospective observational study
por: Miyazaki, Ryosuke, et al.
Publicado: (2022)

Correction to: Clinical Outcome Assessments in Pediatric Patients With Ulcerative Colitis and Crohn’s Disease Receiving Biologics: A Retrospective Cohort Study
Publicado: (2022)

Correction to: Lenacapavir: First Approval
por: Paik, Julia
Publicado: (2023)

A Literature Review of Ozanimod Therapy in Inflammatory Bowel Disease: From Concept to Practical Application
por: Becher, Noah, et al.
Publicado: (2022)

Correction to: Triamcinolone Acetonide Extended-Release: A Review in Osteoarthritis Pain of the Knee
por: Paik, Julia, et al.
Publicado: (2019)

Correction: a murine model of ulcerative colitis: induced with sinusitis-derived superantigen and food allergen. BMC Gastroenterol. 2005, 5:6
por: Yang, Ping-Chang, et al.
Publicado: (2006)

Correction to: Real-World Prescription Pattern and Healthcare Cost Among Patients with Ulcerative Colitis in Japan: A Retrospective Claims Data Analysis
por: Miyazaki, Celine, et al.
Publicado: (2021)

Correction: A multicenter retrospective study aiming to identify patients who respond well to adsorptive granulomonocytapheresis in moderately to severely active ulcerative colitis
por: Yamamoto, Takayuki, et al.
Publicado: (2018)

Correction: A multicenter retrospective study aiming to identify patients who respond well to adsorptive granulomonocytapheresis in moderately to severely active ulcerative colitis
por: Yamamoto, Takayuki, et al.
Publicado: (2018)

Correction: Association of miR-196a-2 and miR-499 variants with ulcerative colitis and their correlation with expression of respective miRNAs
por: Ranjha, Raju, et al.
Publicado: (2017)

Concentration‐QTc Modeling of Ozanimod’s Major Active Metabolites in Adult Healthy Subjects
por: Briggs, Emily, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_68fibpg3l3tak8al8d6tchrpic